Please allow 24 hours or call the pharmacy before picking up your prescription.
Get Healthy!
Results for search "Clinical Trials".
02 Oct
Lead in Consumer Products Remains a Danger to Kids, New Study Finds
Despite years of success in lowering lead exposure, researchers say the toxic metal is still a main source of elevated blood lead levels in children.
Health News Results - 99
Clinical trials sponsored by Big Pharma enrolled eight times as many patients as U.S.-government trials did between 2018 and 2022, new research shows.
The study -- conducted by researchers at Fred Hutch Cancer Center in Seattle -- underscores the lack of investment in federally funded studies and a growing reliance on industry research. The magnitude of the gap researchers identified took...
- Carole Tanzer Miller HealthDay Reporter
- |
- October 1, 2024
- |
- Full Page
Animal studies are often considered a first step in finding new drugs and treatments for human diseases, but a new review has discovered that precious few actually produce real-world therapies.
Only 5% of therapies tested in animals wind up being approved by regulators for human use, according to an analysis of 122 articles involving 54 different diseases and 367 potential treatments.
...- Dennis Thompson HealthDay Reporter
- |
- June 14, 2024
- |
- Full Page
Black and Hispanic patients with Alzheimer's disease are greatly underrepresented in clinical trials, even though they're more likely to get dementia than whites.
However, racial discrimination may not be driving this disparity, a new study finds.
Instead, Black and Hispanic people are being judged in...
- Dennis Thompson HealthDay Reporter
- |
- April 19, 2024
- |
- Full Page
More patients these days are taking part in cancer research, a new study finds.
At least one in five people with cancer (22%) participate in some form of clinical research, when all types of cancer studies are considered, researchers found.
Moreover, enrollment in cancer treatment trials wa...
- Dennis Thompson HealthDay Reporter
- |
- April 3, 2024
- |
- Full Page
For people with tough-to-treat epilepsy, seizures can be both frightening and dangerous, but a new experimental pill may bring significant relief to over one-third of them.
Dubbed XEN1101, the new drug reduced the frequency of seizures by more than 50%, or even eliminated them, in some patients with focal epilepsy who did not respond to an average of six other drugs.
"I am predictin...
- Steven Reinberg HealthDay Reporter
- |
- October 10, 2023
- |
- Full Page
A nasal spray containing a ketamine derivative appears to beat one of the standard drugs used for people with difficult-to-treat depression, a new clinical trial has found.
The trial, of nearly 700 people with treatment-resistant depression, found that esketamine nasal spray was more effective at sending patients into remission than a standard oral drug called quetiapine (Seroquel).
- Amy Norton HealthDay Reporter
- |
- October 5, 2023
- |
- Full Page
People with type 1 diabetes lack functional islet cells in their pancreas to produce the hormone insulin and must take daily insulin via injections or a continuous pump to compensate.
But if new research pans out, some folks with type 1 diabetes may no longer need ...
- Denise Mann HealthDay Reporter
- |
- October 4, 2023
- |
- Full Page
Every day, millions of people must take one or more pills to control their blood pressure and reduce their risk for heart attack or stroke, but if new research pans out, some may be able to scrap their pills for a twice-yearly shot with the same benefits.
Given as a shot every six months, zilebesiran suppresses the gene that produces a hormone called angiotensin that causes blood vessels ...
- Denise Mann HealthDay Reporter
- |
- July 20, 2023
- |
- Full Page
Another experimental drug meant to slow the damage of Alzheimer's appears poised to join a growing arsenal of new treatments for this memory-robbing disease.
In research published online Monday in the Journal of the American Medical Association and presented simultaneously at the Alzheimer's A...
- Robin Foster HealthDay Reporter
- |
- July 17, 2023
- |
- Full Page
Low doses of the eyedrops ophthalmologists use to dilate your pupils during an eye exam are not able to slow the progression of nearsightedness (myopia) in children, a new clinical trial has found.
Atropine eyedrops at a concentration of 0.01% did not outperform placebo drops in slowing either myopia progression or elongation of the eye among children after two years of treatment, the stu...
- Dennis Thompson HealthDay Reporter
- |
- July 13, 2023
- |
- Full Page
The U.S. Food and Drug Administration on Thursday gave full approval to the Alzheimer's drug Leqembi, clearing the way for insurance coverage of the pricey drug.
"The full FDA approval will open the floodgates for people with early Alzheimer's to get this drug. It's a big deal because it's very expensive at $26,500 per year,"
An experimental drug appears to outperform the trendy medications Wegovy and Ozempic for both weight loss and diabetes control, a pair of early clinical trials shows.
Retatrutide helped people with obesity drop about one-quarter of their starting weight, on average, during 48 weeks taking the drug, according to phase 2 trial results published online June 26 in the
Patients with bile duct cancer might soon have an additional treatment available to them, thanks to a newly discovered tumor target.
Some bile duct cancers are driven by a mutated HER2 gene, which has also been implicated in cancers of the breast, esophagus and prostate, researchers report in a new study.
An experimental drug targeting HER2 mutations, zanidatamab, produced powerful ...
- Dennis Thompson HealthDay Reporter
- |
- June 12, 2023
- |
- Full Page
A clinical trial that's attempting to discover a cure for sickle cell disease has found a new gene therapy to be safe and successful in four patients.
Two of the patients were treated at Cleveland Clinic Children's in Ohio, and doctors there are hopeful that their positive results will be borne out in future research.
"New treatments like this are critical for people who have sickle...
- Cara Murez HealthDay Reporter
- |
- June 12, 2023
- |
- Full Page
A safe, generic diabetes pill can help people avoid long COVID, a new clinical trial shows.
Metformin cut the risk of long COVID by about 40% for patients who received a two-week course of the drug while battling their infection, the researchers reported.
The results were even more dramatic if COVID-19 patients began taking metformin soon after infection. Starting on the drug w...
- Dennis Thompson HealthDay Reporter
- |
- June 9, 2023
- |
- Full Page
For years, doctors have thought that a more extensive surgery that removes a wider swath of lymph nodes was the best option for certain patients with bladder cancer. Now, a new clinical trial is upending that belief.
Researchers found that the strategy -- known as extended lymphadenectomy -- was no better than standard surgery at prolonging patients' lives or the amount of time they live...
- Amy Norton HealthDay Reporter
- |
- June 7, 2023
- |
- Full Page
Once-a-day use of the targeted cancer pill Tagrisso (osimertinib) cut the five-year death rate in half for a subset of patients with early-stage lung cancer, a new clinical trial shows.
The results could have major implications for patients whose cancers carry a mutation in a gene known as EGFR, which is implicated in the out-of-control cellular growth driving a tumor. Tagrisso appears to...
- Ernie Mundell HealthDay Reporter
- |
- June 6, 2023
- |
- Full Page
A new study on using nitroglycerin patches to help women with frequent hot flashes caused by menopause has delivered mixed results.
The benefits of wearing these patches -- long used as chest pain medication -- were modest. They also were short-lived, with any benefits appearing to wear off over time, according to researchers from the University of California, San Francisco (UCSF).
- Cara Murez HealthDay Reporter
- |
- June 6, 2023
- |
- Full Page
An experimental targeted therapy can dramatically slow the progress of common slow-growing brain cancers, a new clinical trial finds.
The oral drug vorasidenib nearly tripled progression-free survival in patients with grade 2 gliomas compared to placebo, nearly 28 months versus 11 months, according to results presented Sunday at the American Society of Clinical Oncology (ASCO) annual meet...
- Dennis Thompson HealthDay Reporter
- |
- June 5, 2023
- |
- Full Page
A new liver dialysis device might soon be able to save patients on the edge of death from liver failure, early clinical trial results show.
The DIALIVE device safely improved organ function and alleviated symptoms in patients with acute-on-chronic liver failure, compared with others receiving standard care, the researchers reported.
If the device proves out in a larger trial, it cou...
- Dennis Thompson HealthDay Reporter
- |
- June 2, 2023
- |
- Full Page
A common test for lung function may be missing lung problems in Black men, leading to under-diagnosis and insufficient care.
A new study from the University of Pennsylvania estimates that as many as 40% more Black male patients would have been diagnosed with breathing problems if racial bias hadn't been built into diagnosing software.
At issue is part of a long-held assumption th...
- Cara Murez HealthDay Reporter
- |
- June 2, 2023
- |
- Full Page
An extended-release version of a Parkinson's disease drug could provide more stable relief for patients with the movement disorder, new clinical trial data show.
The new formulation of levodopa, called IPX203, extended the duration of patients' "on time" -- the amount of time the medication is working and symptoms are lessened, researchers reported this week at the American Academy of Ne...
- Dennis Thompson HealthDay Reporter
- |
- April 26, 2023
- |
- Full Page
Whether the gender of a blood donor could affect the recipient's survival was an unanswered question in medicine. Until now.
"Some observational studies had suggested female donor blood might be linked with a higher risk of death among recipients compared to male donor blood, but our clinical trial found that isn't the case,"co-lead author
An experimental targeted drug could provide a fresh chance for people with recurring head and neck cancer that has grown resistant to other treatments, a new clinical trial says.
Ficlatuzumab used in combination with the already approved targeted drug cetuximab (Erbitux) significantly improved progression-free survival in relapsed head and neck cancer patients, according to results from a...
- Dennis Thompson HealthDay Reporter
- |
- April 3, 2023
- |
- Full Page
An experimental injectable drug appears effective in reducing bleeds in patients with hemophilia A and B, according to a pair of new clinical trials.
Two-thirds of people with treatment-resistant hemophilia who were treated with the drug fitusiran had no bleeds at all after nine months, versus just 5% of people treated with drugs that enhance clotting, according to a trial published onlin...
- Dennis Thompson HealthDay Reporter
- |
- March 31, 2023
- |
- Full Page
Cynthia Elford had recently lost her left leg to type 1 diabetes, after a sunburned big toe turned nearly black and forced an amputation.
Now, Elford was being told the same thing was happening in her right leg.
"I went to clip the toenail on the big toe of my right leg and I nipped my skin, just nipped it, and it was enough that it didn't heal,"said Elford, 63, of Hermitage, Pa. "A...
- Dennis Thompson HealthDay Reporter
- |
- March 30, 2023
- |
- Full Page
Patients could soon have access to a new injectable drug to treat atopic dermatitis, the most common form of eczema.
The drug, lebrikizumab, proved effective in teenagers and adults in two clinical trials just published in the New England Journal of Medicine
- Dennis Thompson HealthDay Reporter
- |
- March 20, 2023
- |
- Full Page
A new study is raising questions about the effectiveness of medications long used to prevent painful kidney stones, but experts say there's no reason for patients to toss their prescriptions out at this point.
Anyone who has ever passed a kidney stone would prefer to avoid a repeat experience. And for many years, doctors have prescribed thiazide diuretics as one preventive tactic.
B...
- Amy Norton HealthDay Reporter
- |
- March 6, 2023
- |
- Full Page
Using a "neuroprotectant" drug alongside the standard surgical removal of a clot may slash the risk of death and disability following a stroke, a new study finds.
The new medication, called ApTOLL, shields brain tissue from continuing damage by cooling down inflammation, the researchers said.
A stroke occurs when blood supply to part of the brain is blocked by a clot or when a ...
- Denise Mann HealthDay Reporter
- |
- February 9, 2023
- |
- Full Page
A single injection of an experimental biologic drug may cut in half your risk of hospitalization from COVID-19 infection, new clinical trial results show.
Pegylated lambda interferon (PEG-lambda) proved effective against all COVID-19 variants encountered in this international study, including Omicron, according to findings reported Feb. 9 in the
The best treatment for a genetically driven form of lung cancer continues to show lasting benefits, a new clinical trial update shows.
Tagrisso (osimertinib) nearly doubles disease-free survival in earlier-stage patients whose lung cancer is driven by a mutation in their EGFR (epidermal growth factor receptor) gene, researchers report.
After four years of follow-up, disease-free sur...
- Dennis Thompson HealthDay Reporter
- |
- February 6, 2023
- |
- Full Page
The U.S. Food and Drug Administration on Friday approved a second Alzheimer's drug, lecanemab, despite reports of rare brain bleeds linked to use of the drug in some patients.
However, the FDA pointed to the drug's benefits, as well.
"Alzheimer's disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,"Dr. Billy Dunn,...
- Ernie Mundell HealthDay Reporter
- |
- January 6, 2023
- |
- Full Page
Lecanemab: It's an experimental medication that's been shown in trials to slow cognitive decline in people with Alzheimer's disease.
It's also up for accelerated approval by the U.S. Food and Drug Administration, with a decision expected by Jan. 6.
However, the drug has also been linked to two deaths from brain bleeds among people who've used it in trials, so safety concerns could...
- Ernie Mundell HealthDay Reporter
- |
- January 5, 2023
- |
- Full Page
A relatively new drug is boosting survival rates for women with a specific type of advanced breast cancer who haven't responded to other treatments, according to a pair of clinical trials.
The targeted antibody drug -- trastuzumab deruxtecan (T-DXd, sold under the brand name Enhertu) -- dramatically outperformed an older antibody drug in one trial, quadrupling the number of months wo...
- Dennis Thompson HealthDay Reporter
- |
- December 8, 2022
- |
- Full Page
Two people have now died from brain hemorrhages that may be linked to an experimental Alzheimer's drug, calling into question the medication's safety.
A 65-year-old woman with early-stage Alzheimer's recently died from a massive brain bleed that some researchers link to lecanemab, an antibody drug designed to bind to and remove amyloid-beta from the brain, according to a report published ...
- Dennis Thompson HealthDay Reporter
- |
- November 29, 2022
- |
- Full Page
Infants and children sick with RSV are flooding pediatricians' offices and children's hospitals across the United States, due to an early surge of the common childhood virus this year.
But within one or two "sick seasons,"doctors expect to have on hand long-sought tools to help blunt the impact of respiratory syncytial virus (RSV).
As many as four new RSV vaccine candidates could so...
- Dennis Thompson HealthDay Reporter
- |
- November 7, 2022
- |
- Full Page
New drugs that could slow or prevent the start of dementia would be groundbreaking, but a new poll suggests many middle-aged adults may be reluctant to take part in the studies that test those medications.
Only about 12% of the roughly 1,000 people aged 50 to 64 who were surveyed said they're very likely to step forward to test a new dementia drug, according to the National Poll on Health...
- Cara Murez HealthDay Reporter
- |
- November 4, 2022
- |
- Full Page
Flash radiotherapy, a new technology that uses targeted proton beams, is safe and effective in relieving pain for terminal cancer patients, a new, small study suggests.
Flash radiotherapy delivers radiation at dose rates more than 300 times higher than those used in conventional radiation...
- Steven Reinberg HealthDay Reporter
- |
- October 26, 2022
- |
- Full Page
The ability of TPOXX to treat people infected with monkeypox is being directly tested in a new clinical trial in central Africa, U.S. health officials have announced.
TPOXX -- the antiviral drug tecovirimat -- is only approved to treat
Researchers report early success with using an existing rheumatoid arthritis (RA) drug to treat systemic sclerosis, a rare but potentially devastating autoimmune condition.
The disease, a subset of scleroderma, ha...
- By Cara Murez HealthDay Reporter
- |
- October 10, 2022
- |
- Full Page
Larry Griner resigned from his job in California and moved back to his childhood home in Baltimore nearly five years ago so he could care for his mother, Norma.
She had been diagnosed with Alzheimer's disease almost 12 y...
- Sydney Murphy HealthDay Reporter
- |
- October 3, 2022
- |
- Full Page
Japanese drugmaker Eisai on Wednesday said its experimental drug lecanemab helped slow thinking declines among people in the early stages of Alzheimer's disease.
The findings from a phase 3 clinical trial have yet to be peer-reviewed in any medical journal. But according to a company
An experimental drug that has been shown to treat rashes in people with lupus may also help with lupus-related joint pain.
Affecting as many as 1.5 million people in the United States, lupus is an autoimmune disease in which the body's immune system misfires against its own joints, skin, brain, lungs, kidneys and blood vesse...
- Denise Mann HealthDay Reporter
- |
- September 8, 2022
- |
- Full Page
An experimental antibody therapy for multiple sclerosis can cut symptom flare-ups by half, versus a standard treatment, a new clinical trial has found.
The drug, called ublituximab, beat a standard oral medication for
An experimental new pill could boost treatment of the autoimmune disease lupus, researchers reported at the American Chemical Society's annual meeting.
The pill has been shown in mouse studies to inhibit lupus symptoms, reverse signs of organ damage, and prevent death,
To ensure that all kinds of patients get drugs and devices that are safe and effective for them, they need to be represented in clinical trials, but a new study shows that representation of women in key disease areas conti...
- By Cara Murez HealthDay Reporter
- |
- June 23, 2022
- |
- Full Page
Cancer clinical trials in the United States appear to be rebounding after a significant slowdown during the pandemic, researchers say.
For the study, the investigators analyzed data from the Dana-Farber Cancer Institute in Boston and the Tisch Cancer Institute at Mount Sinai Medical School in New Y...
- By Robert Preidt HealthDay Reporter
- |
- June 15, 2022
- |
- Full Page
A newly approved drug for type 2 diabetes may be a game-changer for treating obesity, too.
Given as a shot once a week, tirzepatide works on two naturally occurring hormones that help tell the brain that you are full. It may be as effective as weight-loss surgery.
"About nine of 10 people in the study lost weight, and the average weight loss for the highest dose was 22.5%, which is ...
- Denise Mann HealthDay Reporter
- |
- June 6, 2022
- |
- Full Page
A small study delivers startling results on the power of a new immunotherapy treatment against rectal cancer: The drug triggered remission in all the patients who got it.
All of them had mismatch repair-deficient (MMRd) locally advanced rectal cancer and were given dostarlimab - an anti-PD-...
- By Robert Preidt HealthDay Reporter
- |
- June 6, 2022
- |
- Full Page
Site Navigation
Contact Us
695 West Tefft Street, Suite A, Nipomo, CA 93444
(805) 929-1929 - (805) 929-2041
2024 © All Rights Reserved. Privacy Policy